Biologie unicellulaire

Abstrait

Anti-Aβ Antibodies in the Fighting with Alzheimer’s Disease

Mehmet Bostanciklioglu

Alzheimer disease (AD) is the most common form of dementia. Amyloid-β plaques have become main therapeutic targets on the basis of growing evidences. Despite hundred studies are designed in animals and humans, the success in this therapeutic approach is still a disappointment. In the present study, the affect mechanism of anti-Aβ antibodies, the type of antibodies and immunization, why despite numerous studies and the huge budget allocated for the researches of AD, the treatment success is limited also what is the last developments in the immunotherapeutic, are reviewed. The necessity of the early treatment of AD is stronger than ever. Therefore, the new studies which target to develop the new conformation specific antibodies and the new techniques that facilitate the crossing of these new conformation specific antibodies to central nervous system (CNS) through blood brain barrier (BBB) should be designed.